Quantal bioassay and stroke

Author(s): Zivin JA, Waud DR

Abstract

Background:Experimental investigation of stroke, in particular the evaluation of therapeutic maneuvers, is difficult because even well-controlled experiments show considerable variability. Optimal use of resources requires efficient statistical analysis.

Summary of review:A body of experience in pharmacology that is directly applicable to stroke studies is reviewed. The general approach, though well known to pharmacologists, is less familiar to neurologists. This paper attempts to give a survey so that neurologists encountering studies using this general class of analysis will better be able to put the technique into context. The general nature of a quantal bioassay is described, the underlying conceptual models are discussed, and specific examples are given.

Conclusions:The pharmacologist's approach to the analysis of quantal bioassays can easily be adapted to the quantification of results in studies of stroke.

Similar Articles

Ischemic stroke subtypes: a population-based study of incidence and risk factors

Author(s): Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, et al.

Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence

Author(s): Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, et al.

Thrombolysis with alteplase 3 to 4

Author(s): Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al.

The science of stroke: mechanisms in search of treatments

Author(s): Moskowitz MA, Lo EH, Iadecola C

von Willebrand factor: an emerging target in stroke therapy

Author(s): De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C

Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins

Author(s): André P, Denis CV, Ware J, Saffaripour S, Hynes RO, et al.

Shear-dependent changes in the three-dimensional structure of human von Willebrand factor

Author(s): Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, et al.

Deficiency of von Willebrand factor protects mice from ischemic stroke

Author(s): Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, et al.

Tissue plasminogen activator reduces neurological damage after cerebral embolism

Author(s): Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA

Tissue plasminogen activator

Author(s): Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, et al.

Neuroprotective effects of anesthetic agents

Author(s): Kawaguchi M, Furuya H, Patel PM